Suppliers / Tianjin Jinjin Pharmaceutical

Tianjin Jinjin Pharmaceutical

China Updated 9 July 2026

Tianjin Jinjin Pharmaceutical is an API manufacturer based in China. It holds 4 active US drug master files across a filed portfolio of 2 molecules. Its GMP standing is certified by MFDS (Korea) and US FDA. Its most recent recorded inspection, by US FDA, closed on 29 March 2024 as VAI.

4
active US DMFs
0
valid CEPs
1
registered plants 1 with an FDA FEI number
0
filings across 0 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Inspections
3 of 3 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.

Inspection history

  • 29 March 2024 VAI US FDA
  • 9 September 2016 NAI US FDA
  • 17 June 2011 NAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
China, China 3003316563

What they file, and where

Molecule Regulators Docs
Hydrocortisone SFDA (Saudi Arabia), US FDA 4
Spironolactone SFDA (Saudi Arabia), US FDA 2

Also appears on these molecule pages

Hydrocortisone API Spironolactone API

Filings and GMP by regulator

Regulator Filings GMP certificates
MFDS (Korea) None 2
US FDA None 1

Comparing suppliers?

Choose your molecules and target markets. Tianjin Jinjin Pharmaceutical comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was VAI, on 29 March 2024.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates